Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

Biotechnology

Healthcare
$15.13 +0.81%

+$0.13 today

Market cap
$2.03B
Beta
1.43
P/E (TTM)
7.2
EPS (TTM)
$2.25
52W Low $7.29High $16.88

Volume 0.76M

Average 1.21M

AUPH Purchases of Investments

Cash used to buy marketable securities and other investments.

Aurinia Pharmaceuticals Inc.NASDAQ: AUPH

Purchases of Investments · Q2 FY2026 · quarter ended Jun 2026

Purchases of investments dips below year-ago levels

Q2 FY2026 purchases of investments of $23.06M (cash outflow) fell 84.1% year over year, behind the +17.5% change in trailing-twelve-month purchases of investments. Sequentially, it fell 81.8% from the prior quarter. Over 3 fiscal years it compounded at +0.2% a year.

Context

  • Purchases of investments amounted to 186.1% of revenue in FY2025, down 46.1 pp from a year earlier.
  • Purchases of investments grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -84.1% toward the trailing-twelve-month pace of +17.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$23.06M-81.8% QoQ
Last fiscal yearDec 2025
-$526.65M-3.5% YoY
LTMJun 2026
-$546.55M+17.5% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-84.1%——
1 year-3.5%——
3-year CAGR+0.2%——
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
(526.65M) USD
Year-over-year change
+3.5%

Purchases of Investments vs competitors

How AUPH compares with its peers on the latest reported figures

  • AUPH's LTM Jun 2026 purchases of investments of $546.55M is the 2nd largest of the 10 companies compared; the peer median is $221.89M.
  • Its year-over-year change of +17.5% is the 4th highest of 9, against a peer median of -11.8%.
  • Purchases of investments amounts to 175.5% of revenue for AUPH, versus a peer median of 5951.0%.
AUPH Competitors Peer median
Purchases of Investments for AUPH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALMSAlumis Inc. Common StockLTM Jun 2026$652.69M +217.4%+0.0%8822.5%
AUPHAurinia Pharmaceuticals Inc.LTM Jun 2026$546.55M +17.5%+0.2%175.5%
VERAVera Therapeutics, Inc.LTM Jun 2026$431.81M -22.1%+27.9%—
EVMNEvommune, Inc.LTM Mar 2026$307.95M ——3079.5%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$235.89M -32.8%+84.5%—
ATTOAttovia Therapeutics, Inc.FY2025$221.89M +382.0%—16436.4%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$172.4M -1.5%——
BHVNBiohaven Ltd.LTM Jun 2026$138.24M -79.7%+0.4%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$81.41M -37.4%-37.8%972.9%
TRAXFirst Tracks Biotherapeutics IncFY2025$0 +100.0%——
Peer median (excluding AUPH) $221.89M-11.8%+0.4%5951.0%

Competitors are the stored peer set for AUPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(180.97M)(108.18M)(78.02M)5.75M287.2M
Depreciation & Amortization2.76M2.71M11.65M19.45M9.27M
Deferred Income Tax0000(176.19M)
Stock-Based Compensation31.24M32.3M45.31M31.6M14.68M
Change in Working Capital(21.63M)(6.82M)(5.61M)5.45M(8.78M)
Accounts Receivables(15.42M)1.93M(10.61M)(12.46M)(4.91M)
Inventory(5.64M)(9.07M)(15.87M)477K(6.46M)
Accounts Payables4.08M(792K)1.24M860K(1.87M)
Other Working Capital(4.65M)1.12M19.63M16.57M4.46M
Other Non-Cash Items10.9M462K(6.79M)(17.85M)9.49M
Operating Cash Flow(157.69M)(79.53M)(33.46M)44.39M135.66M
Capital Expenditures(1.5M)(292K)(718K)(281K)(252K)
Acquisitions (Net)(1.2M)0000
Purchases of Investments(438.96M)(523.99M)(523.5M)(545.83M)(526.65M)
Sales of Investments354.43M464.32M529.38M585.42M494.13M
Other Investing Activities(16.63M)(663K)(11.86M)(43K)0
Investing Cash Flow(103.87M)(60.63M)(6.71M)39.26M(32.77M)
Debt Repayment00(10.03M)(11.99M)(13.14M)
Common Stock Issued196.74M00014.95M
Common Stock Repurchased000(40.24M)(98.16M)
Dividends Paid00000
Other Financing Activities24.37M2.43M4.9M3.14M(9.76M)
Financing Cash Flow221.11M2.43M(5.13M)(49.09M)(106.11M)
Effect of Forex Changes00000
Net Change in Cash(40.45M)(137.73M)(45.3M)34.56M(3.22M)
Free Cash Flow(159.19M)(79.82M)(34.18M)44.11M135.41M

Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

Intrinsic Alpha fair value

Locked

Current Price

$15.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.